Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia | Zendy

Srđan Verstovšek | Zendy; Ayalew Tefferi | Zendy; Hagop M. Kantarjian | Zendy; Taghi Manshouri | Zendy; Raja Luthra | Zendy; Animesh Pardanani | Zendy; Alfonso Quintás-Cardama | Zendy; Farhad Ravandi | Zendy; Pat Ault | Zendy; Carlos E. BuesoRamos | Zendy; Jorge E. Cortés | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

Author(s) -

Srđan Verstovšek,

Ayalew Tefferi,

Hagop M. Kantarjian,

Taghi Manshouri,

Raja Luthra,

Animesh Pardanani,

Alfonso Quintás-Cardama,

Farhad Ravandi,

Pat Ault,

Carlos E. BuesoRamos,

Jorge E. Cortés

Publication year - 2008

Publication title -

clinical cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.427

H-Index - 324

eISSN - 1557-3265

pISSN - 1078-0432

DOI - 10.1158/1078-0432.ccr-08-1302

Subject(s) - alemtuzumab , medicine , hypereosinophilic syndrome , cd52 , monoclonal antibody therapy , eosinophilia , gastroenterology , leukemia , chronic lymphocytic leukemia , bone marrow , surgery , cancer , immunotherapy , transplantation

Patients with hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL) that are refractory to standard therapies are difficult to manage and have significantly shortened life expectancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research